Fagiuoli S, Ravasio R, Lucà MG, Baldan A, Pecere S, Vitale A, Pasulo L. Management of hepatitis C infection before and after liver transplantation. World J Gastroenterol 2015; 21(15): 4447-4456 [PMID: 25914454 DOI: 10.3748/wjg.v21.i15.4447]
Corresponding Author of This Article
Dr. Stefano Fagiuoli, U.S.C Gastroenterology and Transplant Hepatology, Papa Giovanni XXIII Hospital, Piazza OMS, 1, 24127 Bergamo, Italy. sfagiuoli@hpg23.it
Research Domain of This Article
Virology
Article-Type of This Article
Topic Highlight
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Apr 21, 2015; 21(15): 4447-4456 Published online Apr 21, 2015. doi: 10.3748/wjg.v21.i15.4447
Management of hepatitis C infection before and after liver transplantation
Stefano Fagiuoli, Roberto Ravasio, Maria Grazia Lucà, Anna Baldan, Silvia Pecere, Alessandro Vitale, Luisa Pasulo
Stefano Fagiuoli, Maria Grazia Lucà, Anna Baldan, Silvia Pecere, Luisa Pasulo, Gastroenterology and Transplant Hepatology, Papa Giovanni XXIII Hospital, 24127 Bergamo, Italy
Alessandro Vitale, Liver Transplantation and Hepatobiliary Surgical Unit, Padua University Hospital, 35122 Padua, Italy
Author contributions: All authors made substantial contributions to analysis and interpretation of data, drafting the article or making critical revisions related to important intellectual content; and gave final approval of the version of the article to be published.
Conflict-of-interest: Stefano Fagiuoli has lectured or been involved in Advisory boards for MSD, Gilead, BMS, Janssen, Bayer, Roche, Novartis, Biotest, Kedrion and Abbvie. Roberto Ravasio, Maria Grazia Lucà, Anna Baldan, Silvia Pecere, Alessandro Vitale and Luisa Pasulo, have no interests which might be perceived as posing a conflict or bias.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Stefano Fagiuoli, U.S.C Gastroenterology and Transplant Hepatology, Papa Giovanni XXIII Hospital, Piazza OMS, 1, 24127 Bergamo, Italy. sfagiuoli@hpg23.it
Telephone: +39-035-2673459 Fax: +39-035-2674964
Received: December 19, 2014 Peer-review started: December 21, 2014 First decision: January 22, 2015 Revised: February 11, 2015 Accepted: March 12, 2015 Article in press: March 12, 2015 Published online: April 21, 2015 Processing time: 121 Days and 15.6 Hours
Core Tip
Core tip: This paper discusses alternative treatment options for patients with hepatitis C virus (HCV) undergoing liver transplantation (LT), particularly those with decompensated cirrhosis in whom interferon (IFN)-based therapy is contraindicated. Virtually all patients undergoing LT experience HCV recurrence leading to accelerated liver disease and cirrhosis development with reduced graft and patient survival. Novel IFN-free antiviral therapies featuring better efficacy and tolerability in such patients shall increase sustained virologic response rates while decreasing side effects and drug interactions, thus preventing progression of HCV-related liver disease, decreasing the general costs associated with both HCV treatment and worsening of patient health.